PHOTOCURE: PRESENTATION OF VISONAC® PHASE 2b TRIAL RESULTS

Oslo, Norway, May 31, 2012: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, will present its positive results from the Phase 2b study for Visonac, a novel topical treatment under development for moderate to severe acne.

The presentation is held today 15:00 at Hotel Continental, Stortingsgaten 24/26, Oslo, Norway. 

Please find the presentation enclosed.

For further information, please contact:

PhotocurePresident & CEO Kjetil Hestdal
Tel: + 47 913 19 535, Email: kh@photocure.no

M: Communications
Mary Clark, Amber Bielecka, Hollie Vile
Tel: +44 207920 2361, Email: photocure@mcomgroup.com

About Photocure
Photocure ASA is a worldwide leader in photodynamic technology. Listed on the Oslo Stock Exchange (OSE: PHO), Photocure is focused on photodynamic technologies in dermatology and cancer. The company strives to solve unmet needs by developing new and innovative solutions based on its patented Photocure Technology(TM). Photocure markets and sells its own products in selected markets and has developed strong partnerships with leading pharmaceutical companies on a regional and global basis. Photocure's bladder cancer diagnostic product, Cysview/Hexvix is approved in Europe and the US. In addition, the company markets Allumera®, a photodynamic cosmetic in the US. Setting new standards for diagnosis and treatment of several different conditions, Photocure Technology(TM) is continuously being tested for new products and applications in cancer and dermatology.

Visonac®, Allumera®, Photocure® and Cysview®/Hexvix® are registered trademarks of Photocure ASA. For more information about Photocure, visit www.photocure.com.